Dxcover to release data on early detection of multiple-solid tumors at AACR 2022 Annual Meeting

Data highlight high sensitivity of novel infrared spectroscopy approach for stage I disease


SCOTLAND, UK., March 29, 2022



Dxcover Limited, a clinical stage diagnostics company developing its spectroscopic liquid biopsy technology for early detection of multiple cancers, today announced that it will make four presentations at the 2022 American Association for Cancer Research(AACR) Annual Meetingtaking place in New Orleans,Louisiana from April 8-13, 2022. The e-posters will be made availableonline starting Friday, April 8 at 1:00pm ET.


“We are excited to present the validation of our technology for the early detection of brain cancer and to also highlight our ability to detect early-stage cancer, which has now been demonstrated in eight cancers including lung, colon, pancreatic, prostate, ovarian, breast, kidney, and brain. We look forward to progressing our clinical plans with leading clinicians in the USA and Europe,” said Dr Matthew J. Baker, Chief Technical Officer of Dxcover Limited.


Four abstracts (links below) have been accepted for presentation in the Clinical Prevention, Early Detection, and Interception (OPO.PR02.01) session at the conference, which showcase Dxcover’s ability to detect organ specific cancers earlier and perform multi-cancer combination tests:


· 5922 - Prospective clinical validation of a spectroscopic liquid biopsy for early detection of brain cancer in a 988-patient population


· 5920 - Multi-cancer early detection with a spectroscopic liquid biopsy platform


· 5921 - Machine learning based detection of pancreatic tumors using the Dxcover cancer platform


· 5923 - Rapid spectroscopic liquid biopsy for the early detection of brain tumors





About Dxcover Limited


Dxcover’s novel platform combines infrared spectroscopy and machine learning. The tests are simple to use, need a low sample volume, and can deliver same-day results. The company has generated compelling clinical data in >3,000 patient samples across multiple clinical studies. Its prospective brain cancer study indicated 96% sensitivity, while its retrospective MCED study indicated high accuracy across eight cancers at all tumor stages and demonstrated an overall sensitivity of 90% (including 93% sensitivity in Stage I cancers). Dxcover Limited is based in Scotland, United Kingdom and is establishing operations in the USA.


For further information go to https://www.dxcover.com/science


Scientific & Clinical Contact: Dr Matthew J. Baker, Chief Technical Officer Dxcover Limited, matthew.baker@dxcover.com

Investor Contact: Dr Mark Hegarty, Chief Executive Officer Dxcover Limited, mark.hegarty@dxcover.com


Recent Posts

See All

Cancer diagnostics company, Dxcover Limited, has published its latest data from clinical studies on earlier detection of aggressive cancers. The study[i] involving over 980 patients suffering from non